Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,421 to 2,440 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo: Part 1A Number of Participants With a SARS-CoV-2 Infection (Symptomatic or Asymptomatic) | 22 of 2,142 25 of 1,044 | -1.4 points -2.5 to -0.4 | 3,186 | NCT04649151 A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 |
| Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo: Part 1A Number of Participants With Secondary Case Definition of COVID-19 (Center for Disease Control and Prevention [CDC] Case Definition) | 2 of 2,142 9 of 1,044 | -0.8 points -1.5 to -0.3 | 3,186 | NCT04649151 A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 |
| Apixaban 2.5mg BID vs Enoxaparin 30 mg SC Injection q 12 Hours: serious adverse events | 123 of 1,596 123 of 1,588 | -0.0 points -1.9 to 1.8 | 3,184 | NCT00371683 Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery |
| Oral Semaglutide vs Placebo: Time From Randomisation to First Occurrence of a Composite Endpoint Consisting of: All-cause Death, Non-fatal Myocardial Infarction or Nonfatal Stroke | 69 of 1,591 89 of 1,592 | -1.3 points -2.8 to 0.3 | 3,183 | NCT02692716 A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes |
| Oral Semaglutide vs Placebo: Time From Randomisation to First Occurrence of an Expanded Composite Cardiovascular Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, UAP Requiring Hospitalisation or Hospitalisation for Heart Failure | 83 of 1,591 100 of 1,592 | -1.1 points -2.7 to 0.6 | 3,183 | NCT02692716 A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes |
| Oral Semaglutide vs Placebo: Time to First AE Leading to Permanent Trial Product Discontinuation | 184 of 1,591 104 of 1,592 | 5.0 points 3.0 to 7.0 | 3,183 | NCT02692716 A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes |
| Oral Semaglutide vs Placebo: Time From Randomisation to All-cause Death | 23 of 1,591 45 of 1,592 | -1.4 points -2.4 to -0.4 | 3,183 | NCT02692716 A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes |
| Oral Semaglutide vs Placebo: Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke | 61 of 1,591 76 of 1,592 | -0.9 points -2.4 to 0.5 | 3,183 | NCT02692716 A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes |
| Oral Semaglutide vs Placebo: Time From Randomisation to First Occurrence of Fatal or Non-fatal Stroke | 13 of 1,591 17 of 1,592 | -0.3 points -1.0 to 0.5 | 3,183 | NCT02692716 A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes |
| Oral Semaglutide vs Placebo: Time From Randomisation to First Occurrence of Fatal or Non-fatal Myocardial Infarction | 37 of 1,591 35 of 1,592 | 0.1 points -0.9 to 1.2 | 3,183 | NCT02692716 A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes |
| Oral Semaglutide vs Placebo: deaths from any cause | 23 of 1,591 45 of 1,591 | -1.4 points -2.4 to -0.4 | 3,182 | NCT02692716 A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes |
| Oral Semaglutide vs Placebo: serious adverse events | 301 of 1,591 358 of 1,591 | -3.6 points -6.4 to -0.8 | 3,182 | NCT02692716 A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes |
| Intervention vs Control: deaths from any cause | 3 of 1,552 1 of 1,629 | 0.1 points -0.2 to 0.5 | 3,181 | NCT04060667 Wireless Physiologic Monitoring in Postpartum Women |
| Intervention vs Control: serious adverse events | 6 of 1,552 12 of 1,629 | -0.4 points -0.9 to 0.2 | 3,181 | NCT04060667 Wireless Physiologic Monitoring in Postpartum Women |
| Arm 1: MOVE OUT vs Arm 2: MOVE!: serious adverse events | 32 of 1,571 29 of 1,598 | 0.2 points -0.8 to 1.2 | 3,169 | NCT01339390 MOVE OUT: A Partnership With Veterans Groups to Enhance Weight Management in the Veterans Health Administration (VHA) |
| Primary Care Office Visits (Pre Intervention) vs Primary Care Office Visits (Post Intervention): Number of Participants Who Report Thoughts of Self Harm - Patient Health Questionnaire (PHQ-9) in All Practices | 39 of 1,067 116 of 2,102 | -1.9 points -3.3 to -0.3 | 3,169 | NCT05110014 Substudy of Protocol NCT03843957 - Effect of mPATH on Screening for Depression, Fall Risk, and Safety |
| Primary Care Office Visits (Pre Intervention) vs Primary Care Office Visits (Post Intervention): Number of Participants Screening Positive for Fall Risk at Home in All Practices | 907 of 1,067 1,692 of 2,102 | 4.5 points 1.7 to 7.2 | 3,169 | NCT05110014 Substudy of Protocol NCT03843957 - Effect of mPATH on Screening for Depression, Fall Risk, and Safety |
| Primary Care Office Visits (Pre Intervention) vs Primary Care Office Visits (Post Intervention): Number of Participants Screening Positive for Intimate Partner Violence in All Practices | 10 of 1,067 310 of 2,102 | -13.8 points -15.4 to -12.2 | 3,169 | NCT05110014 Substudy of Protocol NCT03843957 - Effect of mPATH on Screening for Depression, Fall Risk, and Safety |
| CDI Cases vs CDI Negative Controls: The Number of Cases of CDI | 103 of 103 0 of 3,050 | 100.0 points 96.4 to 100.0 | 3,153 | NCT03503474 COMBACTE-CDI Understanding the Burden of C. Difficile Infection |
| M-M-R II ® vs Placebo: Number of Participants With Symptomatic COVID-19 at 60 Days | 24 of 1,607 19 of 1,545 | 0.3 points -0.6 to 1.1 | 3,152 | NCT04333732 CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION |
Code
curl "https://conductscience.org/api/comparisons/v1?page=122"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=122
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT04649151-6fef783b",
"title": "Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo: Part 1A Number of Participants With a SARS-CoV-2 Infection (Symptomatic or Asymptomatic)",
"summary": "22 of 2142 against 25 of 1044; risk difference -1.4 points, 95% interval -2.5 to -0.4; NCT04649151, A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19",
"record": "/library/comparisons/NCT04649151-6fef783b",
"nct_id": "NCT04649151",
"kind": "outcome",
"participants": 3186,
"risk_difference": {
"value": -0.013675585176599376,
"lower": -0.025369903275453656,
"upper": -0.004387420578445144
},
"group_1": "22 of 2,142",
"group_2": "25 of 1,044",
"difference": "-1.4 points",
"interval": "-2.5 to -0.4",
"trial_title": "A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19"
},
{
"id": "NCT04649151-b1799155",
"title": "Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo: Part 1A Number of Participants With Secondary Case Definition of COVID-19 (Center for Disease Control and Prevention [CDC] Case Definition)",
"summary": "2 of 2142 against 9 of 1044; risk difference -0.8 points, 95% interval -1.5 to -0.3; NCT04649151, A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19",
"record": "/library/comparisons/NCT04649151-b1799155",
"nct_id": "NCT04649151",
"kind": "outcome",
"participants": 3186,
"risk_difference": {
"value": -0.007686982839112656,
"lower": -0.015398441409124462,
"upper": -0.002921491341910506
},
"group_1": "2 of 2,142",
"group_2": "9 of 1,044",
"difference": "-0.8 points",
"interval": "-1.5 to -0.3",
"trial_title": "A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=123",
"request_id": "SBkE-I3rallAjn2x"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant